Literature DB >> 10565826

Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism.

W Tang1, R A Stearns, G Y Kwei, S A Iliff, R R Miller, M A Egan, N X Yu, D C Dean, S Kumar, M Shou, J H Lin, T A Baillie.   

Abstract

The cytochrome P-450 (CYP)3A4-mediated metabolism of diclofenac is stimulated in vitro by quinidine. A similar effect is observed in incubations with monkey liver microsomes. We describe an in vivo interaction of diclofenac and quinidine that leads to enhanced clearance of diclofenac in monkeys. After a dose of diclofenac via portal vein infusion at 0.055 mg/kg/h, steady-state systemic plasma drug concentrations in three male rhesus monkeys were 87, 104, and 32 ng/ml, respectively (control). When diclofenac was coadministered with quinidine (0.25 mg/kg/h) via the same route, the corresponding plasma diclofenac concentrations were 50, 59, and 18 ng/ml, representing 57, 56, and 56% of control values, respectively. In contrast, steady-state systemic diclofenac concentrations in the same three monkeys were elevated 1.4 to 2.5 times when the monkeys were pretreated with L-754,394 (10 mg/kg i.v.), an inhibitor of CYP3A. Further investigation indicated that the plasma protein binding (>99%) and blood/plasma ratio (0.7) of diclofenac remained unchanged in the presence of quinidine. Therefore, the decreases in plasma concentrations of diclofenac after a combined dose of diclofenac and quinidine are taken to reflect increased hepatic clearance of the drug, presumably resulting from the stimulation of CYP3A-catalyzed oxidative metabolism. Consistent with this proposed mechanism, a 2-fold increase in the formation of 5-hydroxydiclofenac derivatives was observed in monkey hepatocyte suspensions containing diclofenac and quinidine. Stimulation of diclofenac metabolism by quinidine was diminished when monkey liver microsomes were pretreated with antibodies against CYP3A. Subsequent kinetic studies indicated that the K(m) value for the CYP-mediated conversion of diclofenac to its 5-hydroxy derivatives was little changed (75 versus 59 microM), whereas V(max) increased 2.5-fold in the presence of quinidine. These data suggest that the catalytic capacity of monkey hepatic CYP3A toward diclofenac metabolism is enhanced by quinidine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10565826

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Multiple ligand docking by Glide: implications for virtual second-site screening.

Authors:  Márton Vass; Ákos Tarcsay; György M Keserű
Journal:  J Comput Aided Mol Des       Date:  2012-05-26       Impact factor: 3.686

2.  Fundamentals of Enzyme Kinetics: Michaelis-Menten and Non-Michaelis-Type (Atypical) Enzyme Kinetics.

Authors:  Eleanore Seibert; Timothy S Tracy
Journal:  Methods Mol Biol       Date:  2021

3.  Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions.

Authors:  Anna L Blobaum; Thomas M Bridges; Frank W Byers; Mark L Turlington; Margrith E Mattmann; Ryan D Morrison; Claire Mackie; Hilde Lavreysen; José M Bartolomé; Gregor J Macdonald; Thomas Steckler; Carrie K Jones; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer; J Scott Daniels
Journal:  Drug Metab Dispos       Date:  2013-09-03       Impact factor: 3.922

4.  The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4.

Authors:  Arthur G Roberts; Jing Yang; James R Halpert; Sidney D Nelson; Kenneth T Thummel; William M Atkins
Journal:  Biochemistry       Date:  2011-11-22       Impact factor: 3.162

5.  Diclofenac and ketoprofen liver toxicity in rat.

Authors:  Zdenko Tomic; Boris Milijasevic; Ana Sabo; Lalosevic Dusan; Vida Jakovljevic; Momir Mikov; Satman Majda; Velibor Vasovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

6.  Energetics of heterotropic cooperativity between alpha-naphthoflavone and testosterone binding to CYP3A4.

Authors:  Arthur G Roberts; William M Atkins
Journal:  Arch Biochem Biophys       Date:  2007-04-02       Impact factor: 4.013

7.  Evaluation of capacity-limited first-pass effect through liver by three-points sampling in portal and hepatic veins and systemic artery.

Authors:  Shinya Ueda; Kiyoshi Yamaoka; Jyoji Yui; Akio Shigematsu; Terumichi Nakagawa
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

8.  In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine.

Authors:  Anand Joshi; Brian F Kiesel; Nupur Chaphekar; Reyna Jones; Jianxia Guo; Charles A Kunos; Sarah Taylor; Edward Chu; Raman Venkataramanan; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2020-09-28       Impact factor: 3.333

9.  A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo.

Authors:  Anna L Blobaum; Frank W Byers; Thomas M Bridges; Charles W Locuson; P Jeffrey Conn; Craig W Lindsley; J Scott Daniels
Journal:  Drug Metab Dispos       Date:  2015-08-11       Impact factor: 3.922

10.  Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.

Authors:  J Yang; W M Atkins; N Isoherranen; M F Paine; K E Thummel
Journal:  Clin Pharmacol Ther       Date:  2011-11-02       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.